

B-Cell Chronic Lymphocytic Leukemia Treatment -EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/B49CA983FA6MEN.html>

Date: March 2018

Pages: 130

Price: US\$ 3,480.00 (Single User License)

ID: B49CA983FA6MEN

Abstracts

Report Summary

B-Cell Chronic Lymphocytic Leukemia Treatment -EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on B-Cell Chronic Lymphocytic Leukemia Treatment industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of B-Cell Chronic Lymphocytic Leukemia Treatment 2013-2017, and development forecast 2018-2023

Main market players of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA, with company and product introduction, position in the B-Cell Chronic Lymphocytic Leukemia Treatment market

Market status and development trend of B-Cell Chronic Lymphocytic Leukemia Treatment by types and applications

Cost and profit status of B-Cell Chronic Lymphocytic Leukemia Treatment, and marketing status

Market growth drivers and challenges

The report segments the EMEA B-Cell Chronic Lymphocytic Leukemia Treatment market as:

EMEA B-Cell Chronic Lymphocytic Leukemia Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe
Middle East
Africa

EMEA B-Cell Chronic Lymphocytic Leukemia Treatment Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

AMG-319
ATTCK-20
IDD-002
JNJ-64052781
Lenalidomide
MAT-303
MT-3724
Others

EMEA B-Cell Chronic Lymphocytic Leukemia Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Clinic
Hospital
Others

EMEA B-Cell Chronic Lymphocytic Leukemia Treatment Market: Players Segment Analysis (Company and Product introduction, B-Cell Chronic Lymphocytic Leukemia Treatment Sales Volume, Revenue, Price and Gross Margin):

AB Science SA
Amgen Inc.
Celgene Corporation
Dynavax Technologies Corporation
Eisai
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd.
iDD biotech SAS
Immunomedics, Inc.
Johnson & Johnson
Juno Therapeutics Inc.
Molecular Templates Inc.
Noxxon Pharma AG

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT

1.1 Definition of B-Cell Chronic Lymphocytic Leukemia Treatment in This Report

1.2 Commercial Types of B-Cell Chronic Lymphocytic Leukemia Treatment

1.2.1 AMG-319

1.2.2 ATTCK-20

1.2.3 IDD-002

1.2.4 JNJ-64052781

1.2.5 Lenalidomide

1.2.6 MAT-303

1.2.7 MT-3724

1.2.8 Others

1.3 Downstream Application of B-Cell Chronic Lymphocytic Leukemia Treatment

1.3.1 Clinic

1.3.2 Hospital

1.3.3 Others

1.4 Development History of B-Cell Chronic Lymphocytic Leukemia Treatment

1.5 Market Status and Trend of B-Cell Chronic Lymphocytic Leukemia Treatment 2013-2023

1.5.1 EMEA B-Cell Chronic Lymphocytic Leukemia Treatment Market Status and Trend 2013-2023

1.5.2 Regional B-Cell Chronic Lymphocytic Leukemia Treatment Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA 2013-2017

2.2 Consumption Market of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Regions

2.2.1 Consumption Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Regions

2.2.2 Revenue of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Regions

2.3 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Regions

2.3.1 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe 2013-2017

2.3.2 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Middle East 2013-2017

2.3.3 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Africa 2013-2017

2.4 Market Development Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA 2018-2023

2.4.1 Market Development Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA 2018-2023

2.4.2 Market Development Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types

3.1.1 Consumption Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Types

3.1.2 Revenue of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Downstream Industry

4.2 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Major Countries

4.2.1 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Europe

4.2.2 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Middle East

4.2.3 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Africa

4.3 Market Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT

5.1 EMEA Economy Situation and Trend Overview

5.2 B-Cell Chronic Lymphocytic Leukemia Treatment Downstream Industry Situation and Trend Overview

CHAPTER 6 B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Major Players

6.2 Revenue of B-Cell Chronic Lymphocytic Leukemia Treatment in EMEA by Major Players

6.3 Basic Information of B-Cell Chronic Lymphocytic Leukemia Treatment by Major Players

6.3.1 Headquarters Location and Established Time of B-Cell Chronic Lymphocytic Leukemia Treatment Major Players

6.3.2 Employees and Revenue Level of B-Cell Chronic Lymphocytic Leukemia Treatment Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AB Science SA

7.1.1 Company profile

7.1.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.1.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of AB Science SA

7.2 Amgen Inc.

7.2.1 Company profile

7.2.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.2.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Amgen Inc.

7.3 Celgene Corporation

7.3.1 Company profile

7.3.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.3.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Celgene Corporation

7.4 Dynavax Technologies Corporation

7.4.1 Company profile

7.4.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.4.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Dynavax Technologies Corporation

7.5 Eisai

7.5.1 Company profile

7.5.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.5.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Eisai

7.6 Elsalys Biotech SAS

7.6.1 Company profile

7.6.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.6.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Elsalys Biotech SAS

7.7 F. Hoffmann-La Roche Ltd.

7.7.1 Company profile

7.7.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.7.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.

7.8 iDD biotech SAS

7.8.1 Company profile

7.8.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.8.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of iDD biotech SAS

7.9 Immunomedics, Inc.

7.9.1 Company profile

7.9.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.9.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Immunomedics, Inc.

7.10 Johnson & Johnson

7.10.1 Company profile

- 7.10.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
- 7.10.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.11 Juno Therapeutics Inc.
 - 7.11.1 Company profile
 - 7.11.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
 - 7.11.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Juno Therapeutics Inc.
- 7.12 Molecular Templates Inc.
 - 7.12.1 Company profile
 - 7.12.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
 - 7.12.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Molecular Templates Inc.
- 7.13 Noxxon Pharma AG
 - 7.13.1 Company profile
 - 7.13.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
 - 7.13.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Noxxon Pharma AG

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF B-CELL CHRONIC LYMPHOCYtic LEUKEMIA TREATMENT

- 8.1 Industry Chain of B-Cell Chronic Lymphocytic Leukemia Treatment
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF B-CELL CHRONIC LYMPHOCYtic LEUKEMIA TREATMENT

- 9.1 Cost Structure Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment
- 9.2 Raw Materials Cost Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment
- 9.3 Labor Cost Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment
- 9.4 Manufacturing Expenses Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment

CHAPTER 10 MARKETING STATUS ANALYSIS OF B-CELL CHRONIC LYMPHOCYtic LEUKEMIA TREATMENT

- 10.1 Marketing Channel

- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: B-Cell Chronic Lymphocytic Leukemia Treatment -EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/B49CA983FA6MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B49CA983FA6MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

